Clinical Trial Update: Phase Ib Study of Axatilimab in Combination With Olaparib in BRCA1/2 and PALB2- Associated Metastatic HER2-negative Breast Cancer [Phase 1]

View source ↗

Summary

This clinical trial update describes a Phase Ib study evaluating Axatilimab in combination with Olaparib for BRCA1/2- and PALB2-associated metastatic HER2-negat…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Breast Cancer with Brca1 Mutation
• Breast Cancer with Brca2 Mutation
• Breast Cancer with Palb2 Mutation

Drugs mentioned

• Axatilimab (axatilimab)
• Lynparza (olaparib)

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: Breast Cancer, PALB2-Mutated Breast Carcinoma | Phase 1 | Status: RECRUITING